GAMRIC 2026: Amprologix heads to Lisbon
1 October 2026In September 2026, the whole Amprologix team travelled to Lisbon for GAMRIC 2026: the Global Antimicrobial Resistance Innovators Conference, organised…
In September 2026, the whole Amprologix team travelled to Lisbon for GAMRIC 2026: the Global Antimicrobial Resistance Innovators Conference, organised…
We are pleased to share the publication of a new peer-reviewed study in the Journal of Antimicrobial Chemotherapy – Antimicrobial…
From 17th-22nd April, Mat and Vicky headed to Munich, Germany for ESCMID GLOBAL 2026
Last week, CSO Mat Upton and CEO Gordon Barker travelled to Basel, Switzerland for the BEAM Alliance 10th AMR meeting.…
On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in…
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is delighted to receive confirmation of its success in securing a £1M Biomedical Catalyst award from Innovate UK for its Tobraderm project. The project will advance the company’s NI01 lead compound through late-preclinical testing for common […]
